Ocugen to detail OCU410 gene therapy imaging and safety data at ASRS
The July 17 presentation extends Ocugen's preliminary ArMaDa readout with imaging and safety detail, testing whether the 31% lesion-growth reduction holds up in a subretinal gene therapy field with no approved disease-modifying option.
Executive Summary
- Ocugen will put imaging and safety detail behind a subretinal gene therapy result it already disclosed, giving retina specialists their first look at how the anatomic data support the topline effect.
- The company has reported a lesion-growth reduction at 12 months with a favorable early safety profile, and this presentation is where independent physicians get to scrutinize the imaging evidence behind that claim.
- Geographic atrophy has no gene therapy approved to slow disease progression, and OCU410's subretinal, one-time dosing approach sits among a small cluster of early-stage gene therapy programs testing whether a single administration can outperform the repeat-injection complement inhibitors already on the market.
- The trial's design, enrollment, and regulatory posture stay as previously set, so the presentation's value lies in verifying the durability and mechanism of an effect already claimed rather than in new trial-level news.
The presentation
Ocugen, Inc. (NASDAQ: OCGN) will present "Phase 1/2 OCU410 Quantitative FAF/SD-OCT Analysis and Safety Outcomes" at the American Society of Retina Specialists conference in Montreal on July 17, 2026, delivered by Jay Chhablani, MD, of the University of Pittsburgh and UPMC Vision Institute. The talk follows immediately after a separate presentation of 1-year results from the same ArMaDa study, delivered by Arshad Khanani, MD, of Sierra Eye Associates. Both draw on NCT06018558, the Phase 1/2 ArMaDa trial testing a single subretinal injection of OCU410 in adults with geographic atrophy. Ocugen+1Ocugen to Participate in Upcoming July Industry ConferencesJul 1, 2026Study to Assess the Safety and Efficacy of OCU410 for Geographic AtrophyNCT06018558
Probability of SuccessBased on the AppliedXL Probability of Success model. For more information about the methodology, read the research here.
The result behind it
Ocugen already disclosed the topline number this imaging data will support: a statistically significant 31% reduction in geographic atrophy lesion growth at the medium and optimal OCU410 doses at 12 months, alongside 27% preservation of the ellipsoid zone and a favorable tolerability profile. A separate March 2026 report described a 46% reduction in macular lesion growth versus control at 12 months with no OCU410-related serious adverse events reported. The ASRS session on fundus autofluorescence (imaging that maps retinal pigment loss) and OCT (a cross-sectional retinal scan) is where the underlying anatomic measurements behind those topline figures get examined by retina specialists directly. OcugenOcugen to Participate in Upcoming July Industry ConferencesJul 1, 2026
Trial mechanics
The registered primary endpoints for NCT06018558 span visual acuity, low-luminance visual acuity, ocular anatomy by ophthalmoscopy and slit lamp exam, intraocular pressure, and ocular and non-ocular adverse events, run against an anticipated enrollment of 63 adults with a defined geographic atrophy lesion area. The trial's primary completion date moved from an original March 2026 target to September 2025 in October 2023, then to February 2026 when the trial's status shifted to Active, not recruiting in May 2025 alongside a modest reduction in target enrollment from 63 to 60. That enrollment change sits within the routine range the operational risk model itself treats as typical, not a threshold-crossing cut. NCT06018558Study to Assess the Safety and Efficacy of OCU410 for Geographic AtrophyNCT06018558
The competitive frame
Geographic atrophy currently has two approved complement inhibitors requiring repeat intravitreal injection, and no approved gene therapy that could deliver durable effect from a single dose. Among gene therapy programs in the indication, OCU410 sits alongside Gyroscope's GT005, Complement Therapeutics' exagamglogene autotemcel program, and Kriya Therapeutics' KRIYA-825, all early-phase and modality-matched but targeting different genes. None has reported a resolved late-stage outcome yet, so the imaging data Ocugen presents this week functions as an early test of whether gene replacement can produce an anatomic effect that a single administration can sustain, against a field where the mechanism itself is read as unvalidated in geographic atrophy.
This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.